Advertisement

Ticked off the list

Botulinum toxin A injections provide relief from tics in patients with Tourette syndrome.

August 30, 2000

NEW YORK, Aug 29 (Praxis Press). Botulinum toxin A (BTX) is an effective treatment for an increasing number of conditions characterized by abnormal muscle contractions. However, its safety and efficacy in the treatment of tics in patients with Tourette syndrome (TS) has not been well studied. To evaluate BTX for this purpose, Kwak and colleagues studied 35 patients (30 male, 5 female) by injecting them with BTX in the sites of their most problematic tics. They evaluated the response to BTX based on a 0 to 4 clinical rating scale (0, no improvement, to 4, marked improvement in both severity and function). In addition, questionnaires were administered to evaluate patients' impressions of overall efficacy and degree of benefit with premonitory sensations. They found that 21 out of 25 patients with premonitory sensations derived marked relief of these symptoms. They also found that the mean peak-effect response in 35 patients treated in 115 sessions was 2.8 (range, 0–4); the mean duration of benefit was 14.4 weeks (maximum, 45 weeks); and the mean latency to onset of benefit was 3.8 days. Botulinum toxin A injections are an effective and well-tolerated treatment of tics and provide relief of premonitory sensations in addition to improving the motor component of tics.

Advertisement

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Advertisement
Mettler Toledo
BD Biosciences
BD Biosciences